Cargando…
Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial
Background: We aimed to compare long-term outcomes in Polish patients with atrial fibrillation (AF) according to oral anticoagulation (OAC) type and to evaluate the predictive value of common thromboembolic and bleeding risk scores. Methods: Data from the CRAFT trial (NCT02987062) were included. The...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073861/ https://www.ncbi.nlm.nih.gov/pubmed/33921867 http://dx.doi.org/10.3390/jcm10081780 |
_version_ | 1783684227185770496 |
---|---|
author | Balsam, Paweł Lodziński, Piotr Gawałko, Monika Kraj, Leszek Śliwczyński, Andrzej Maciejewski, Cezary Krzowski, Bartosz Tymińska, Agata Ozierański, Krzysztof Grabowski, Marcin Bednarski, Janusz Opolski, Grzegorz |
author_facet | Balsam, Paweł Lodziński, Piotr Gawałko, Monika Kraj, Leszek Śliwczyński, Andrzej Maciejewski, Cezary Krzowski, Bartosz Tymińska, Agata Ozierański, Krzysztof Grabowski, Marcin Bednarski, Janusz Opolski, Grzegorz |
author_sort | Balsam, Paweł |
collection | PubMed |
description | Background: We aimed to compare long-term outcomes in Polish patients with atrial fibrillation (AF) according to oral anticoagulation (OAC) type and to evaluate the predictive value of common thromboembolic and bleeding risk scores. Methods: Data from the CRAFT trial (NCT02987062) were included. The primary study endpoint was major adverse event (MAE; all-cause death, thromboembolic and hemorrhagic event) during the mean four-year follow-up period. Results: Out of 2983 patients with available follow-up data, 1686 (56%) were prescribed with vitamin K antagonist (VKA), 891 (30%) with rivaroxaban and 406 (14%) with dabigatran. Predominance of elderly and female patients with previous history of thromboembolic and hemorrhagic events was observed within rivaroxaban (vs. other OAC) group. Higher rate of MAEs and its components was observed in patients on VKA followed by rivaroxaban as compared to patients on dabigatran (43% vs. 42% vs. 31%, p < 0.01). After group matching based on clinical characteristics, higher risk of hemorrhagic events in VKA (vs. dabigatran) and rivaroxaban (vs. dabigatran) group were observed. The available thromboembolic (CHA(2)DS(2)-VASs, ATRIA, R(2)CHADS(2)) and bleeding (HAS-BLED, ATRIA, ORBIT) risk scores showed poor prediction value. Conclusions: Despite no difference in the thromboembolic event rate, treatment with VKA and rivaroxaban was associated with a significant increase in the risk of hemorrhagic events. |
format | Online Article Text |
id | pubmed-8073861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80738612021-04-27 Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial Balsam, Paweł Lodziński, Piotr Gawałko, Monika Kraj, Leszek Śliwczyński, Andrzej Maciejewski, Cezary Krzowski, Bartosz Tymińska, Agata Ozierański, Krzysztof Grabowski, Marcin Bednarski, Janusz Opolski, Grzegorz J Clin Med Article Background: We aimed to compare long-term outcomes in Polish patients with atrial fibrillation (AF) according to oral anticoagulation (OAC) type and to evaluate the predictive value of common thromboembolic and bleeding risk scores. Methods: Data from the CRAFT trial (NCT02987062) were included. The primary study endpoint was major adverse event (MAE; all-cause death, thromboembolic and hemorrhagic event) during the mean four-year follow-up period. Results: Out of 2983 patients with available follow-up data, 1686 (56%) were prescribed with vitamin K antagonist (VKA), 891 (30%) with rivaroxaban and 406 (14%) with dabigatran. Predominance of elderly and female patients with previous history of thromboembolic and hemorrhagic events was observed within rivaroxaban (vs. other OAC) group. Higher rate of MAEs and its components was observed in patients on VKA followed by rivaroxaban as compared to patients on dabigatran (43% vs. 42% vs. 31%, p < 0.01). After group matching based on clinical characteristics, higher risk of hemorrhagic events in VKA (vs. dabigatran) and rivaroxaban (vs. dabigatran) group were observed. The available thromboembolic (CHA(2)DS(2)-VASs, ATRIA, R(2)CHADS(2)) and bleeding (HAS-BLED, ATRIA, ORBIT) risk scores showed poor prediction value. Conclusions: Despite no difference in the thromboembolic event rate, treatment with VKA and rivaroxaban was associated with a significant increase in the risk of hemorrhagic events. MDPI 2021-04-19 /pmc/articles/PMC8073861/ /pubmed/33921867 http://dx.doi.org/10.3390/jcm10081780 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Balsam, Paweł Lodziński, Piotr Gawałko, Monika Kraj, Leszek Śliwczyński, Andrzej Maciejewski, Cezary Krzowski, Bartosz Tymińska, Agata Ozierański, Krzysztof Grabowski, Marcin Bednarski, Janusz Opolski, Grzegorz Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial |
title | Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial |
title_full | Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial |
title_fullStr | Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial |
title_full_unstemmed | Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial |
title_short | Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial |
title_sort | antithrombotic management and long-term outcomes of patients with atrial fibrillation. insights from craft trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073861/ https://www.ncbi.nlm.nih.gov/pubmed/33921867 http://dx.doi.org/10.3390/jcm10081780 |
work_keys_str_mv | AT balsampaweł antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT lodzinskipiotr antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT gawałkomonika antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT krajleszek antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT sliwczynskiandrzej antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT maciejewskicezary antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT krzowskibartosz antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT tyminskaagata antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT ozieranskikrzysztof antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT grabowskimarcin antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT bednarskijanusz antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial AT opolskigrzegorz antithromboticmanagementandlongtermoutcomesofpatientswithatrialfibrillationinsightsfromcrafttrial |